CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, MIDDLE MARKET, J.P. MORGAN COMMERCIAL BANKING
"While the underlying business model for life sciences companies hasn’t changed as a result of our current environment, we’re seeing that increased capital has been made available to those seeking funding. This makes it an incredibly promising time for the sector."
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."
EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, REGENERON
Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.
Aphios explains its developments in Critical Fluid Inactivation, cannabidiol in the area of cancer-induced peripheral neuropathic pain, and combination therapeutics and methods for the treatment of neurodegenerative diseases.
As the second half of 2024 approaches, Peru stands at a crossroads. According to the latest figures, the Democratic Republic of Congo has surpassed Peru as the second-largest copper producer. Cabinet changes under Boluarte's administration and ongoing corruption cases have taken a toll on investor confidence, and illegal mining remains a pressing issue. However, not everything is lost for the Andean country, and the mining sector presents growth opportunities.